Setrusumab
- Generic Name
- Setrusumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1847394-95-9
- Unique Ingredient Identifier
- FPW3780T3E
- Background
Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
- Associated Conditions
- -
- Associated Therapies
- -
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in ...
Ultragenyx Pharmaceutical Inc. received Breakthrough Therapy Designation from the FDA for setrusumab (UX143) to reduce fracture risk in osteogenesis imperfecta (OI) Type I, III, or IV patients aged 2 and older. The designation is based on positive Phase 2 study results showing a decrease in fracture rate.
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma's CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18. The company focuses on rare diseases, with product candidates setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo also has oncology candidates etigilimab and navicixizumab in development.
Small Business - The Stanly News & Press
Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization. Forward-looking statements caution about risks and uncertainties in clinical development and business operations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath